DATE: October 29, 2019
TIME: 8:00am PDT
Although immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some patients do not respond, or stop responding within the first year of therapy. Identifying the underlying mechanisms associated with these variable response rates remains an important open research challenge in clinical oncology.
Join this free webinar to learn how researchers are integrating cell sorting, RNA sequencing, ex-vivo phenotype profiling, and patient-derived xenografts to study the mechanisms of PD-L1 resistance in cancer.
Who Should Attend:
Researchers who want to integrate a multi-omics approach in their clinical studies on immune checkpoint inhibitor resistance will gain valuable insights. In addition, the webinar will benefit those who want to learn about new technologies for isolating and profiling tumor cells.
Review how a multi-omics approach can be used to study the resistance mechanisms to therapies targeting immune checkpoint inhibitors.
Evaluate how new clinical research tools can uncover complexities of tumors and their ecosystems.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
WAVE Newsletter Promotion10%
Trending Newsletter Promotion5%
Medical Laboratory Technician7%
Clinical Laboratory Scientist4%
Life Science Company4%
Manufacturer & Biotech/pharma1%
Contract Research Organization (Cro)1%